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Abstract
Oleanolic acid (OA) is a natural triterpenoid possessing anti-inflammatory, antitumor, antiviral, hepatoprotective and
antihyperlipidemic effects. Research on the pharmacological activities and clinical applications of OA has made
significant progress in the past decade, particularly in the areas such as isolation and purification, chemical
modifications, pharmacological research, toxicity studies and clinical use of OA. However, due to its poor aqueous
solubility, instability and low bioavailability, OA’s clinical applications are still rather limited. Recently,
nanoparticulate drug delivery as the biological dimension of nanotechnology has been developed, which may help
generate useful formulations of OA for clinical applications. Nanoparticulate drug delivery system enhances the
dissolution rate and bioavailability of OA, providing a feasible formulation method for clinical applications.
Introduction
Oleanolic acid (OA), a naturally occurring pentacyclic tri-
terpenoid extracted from the leaves and roots of Olea
europaea, Viscum album L., Aralia chinensis L. and over
120 other plant species [1], is chemically known as 3b-
hydroxy-olea-12-en-28-oic acid [2] (Figure 1). OA exhi-
bits many biological activities such as anti-inflammatory,
antitumor, antiviral, hepatoprotective and anti-hyperlipi-
demic effects. OA has been used in Chinese medicine to
treat liver disorders for over 20 years [2]. Conventional
formulations of OA are tablets and capsules [3]; however,
OA’s poor aqueous solubility and low bioavailability in
vivo make it necessary to develop new formulations for
clinical applications.
Derived from nanotechnology, nanoparticulate delivery
system provides an innovative approach to drug delivery
[4-7]; nanoparticulate technique reduces particles to
nanometer ranges, thus reducing the dose and reactive
nature of the molecule [8]. Various nanoparticulate drug
delivery systems have been explored, such as nanoparti-
cles, nanospheres, nanocapsules, solid lipid nanoparticles
(SLN), self-emulsifying drug delivery systems (SEDDS)
and submicron/nanoemulsions [9][10]. Compared to
conventional dosage forms, nanoparticulate drug deliv-
ery system has many advantages, namely enhancement
of solubility and stability, protection from toxicity,
enrichment of pharmacological activities, improvement
of tissue macrophage distribution, bioavailability and
sustained delivery, protection from physical and chemi-
cal degradation [7,11].
This article reviews recent advances in nanoparticulate
formulation of OA.
Solid lipid nanoparticles
Solid lipid nanoparticles (SLN), which remain solid at
room temperature, have emerged as a new pharmaceuti-
cal delivery system or formulation to modify the release
profile for many drugs [12]. SLN has characteristics of
drug carriers such as lipophilicity, hydrophilicity as well
as low bio-toxicity. Main advantages of SLN include:
controlling drug release, targeting with reduced toxicity,
increasing drug stability and high drug payload [13].
High pressure homogenization is an established
method for SLN production. Film-ultrasound dispersion
technique is another rational and practicable method for
developing a new OA injection [9]. A study showed that
the OA solid lipid nanoparticles (OA-SLN) by film-
ultrasound dispersion technique were with the diameter
(62.0 ± 10.3) (mean ± standard deviation) nm, encapsu-
lation efficiency (98.29%), loading rate (8.17%) in OA-
SLN [9]. In another study, the researchers prepared OA
solid lipid nanoparticles using the optimal preparation
conditions (ultrasonic wave time 40 min, OA-phospholi-
pids (1:8), 60 g/L mannitol 15 mL) by film-ultrasonic
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wave dispersion technique; the appearance of the pre-
pared solid lipid nanoparticles was regular round or
ellipse and the diameter distribution was (75 ± 20.3)
nm; the envelopment ratio was over 97. 81% [14].
Exploring the protective effect of galactoside - modi-
fied OA solid lipid nanoparticles (OA-G10SLN) on
CCl4-induced acute hepatic injury of rats in an in vivo
study, Wang et al. [15] found that the serum levels of
AST and ALT in OA-G10SLN group decreased remark-
ably compared with a model group, and that the degen-
eration and necrosis of liver tissues were alleviated
significantly, with efficacy better than that in the OA
regular solution group.
Nanosuspension
Nanosuspension technology has been used to increase
the solubility, dispersity and homogenization, intrave-
nous injectability, simple production process, universal
adaptivity of poorly water soluble drugs [16]. In addi-
tion, the formation of suspensions is much more appro-
priate at low cost and with simple technology to yield a
more stable product [16].
There are two major methods for preparing nanosus-
pension, namely (1) high-pressure homogenization and
(2) nanoprecipitation. Homogenization pressure is the
major factor determining the average particle size:
increased homogenization cycles led to a decreased poly-
dispensible index [17] and surfactants helped keep the
system stable [10]. The solubility and dissolution of drug
nanoparticles were better than crude drug powder [10].
Researchers obtained OA nanosuspensions with average
particle size of 284.9 nm using this method. Drug in the
form of spherical or near-spherical nanoparticles in the
nanosuspensions showed a faster drug dissolution rate
[18]. Pre-treatment of cells with OA nanosuspensions
significantly enhanced the hepatoprotective effect against
carbon tetrachloride-induced liver injury through lower-
ing serum alanine aminotransferase (ALT) activity and
liver malondialdehyde content [18].
In a formulation study [19], several cryoprotectants
were employed to study the protective effects of the
freeze-dried OA-loaded nanosuspensions. The optimum
formulation was selected according to the mean particle
sizes of samples before and after the freeze-drying pro-
cess. The particles of the best sample achieved a mean
particle size of 236.3 nm and a much higher polydisper-
sity index of 0.242 [19]. The study showed that the opti-
mum lyophilized powder could be obtained with 10%
sucrose as a cryoprotectant.
Nanocapsules
Loading of drugs into ultrafine host vesicles or colloidal
capsules in the nanometer size range was recognized as
a technique to optimize controlled drug delivery [20].
Nanocapsules are designed to improve stability, absorp-
tion, quantitative tissular transfer and pharmacodynamic
activity. Furthermore, they avoided side effects and for-
eign body irritation with better local and systemic toler-
ance during and after medication [20].
Dynamic penetration system for sustained OA release
from the nanocapsules showed that an HPLC profile
curve of the OA loaded nanocapsules fitting the Weibull
equation. It was demonstrated that OA loaded nanocap-
sules sustained the release of OA with a t1/2 about 6.7
times of the control [21].
Liposomes
A liposome is a vesicle consisting of a flexible bilayer
and surrounded by an aqueous core domain. Liposomes
were used to improve the therapeutic activity and safety
of drugs for the past few decades. Advantages of lipo-
somes include high biocompatibility, easy preparation,
high chemical versatility and simple modulation of their
pharmacokinetic properties by changing the chemical
composition of the bilayer components [22].
OA liposomes were prepared with film-ultrasound
technique; optimal formulation and preparation techni-
ques were selected through a test of orthogonal design
and evaluated according to the entrapment rates and
confirmed liposomes [23]. Selected formulation and pre-
paration technique of OA liposomes consistently
achieved regular liposomes with an average size of 182
nm and entrapment rate of 92.91%. Chen et al. prepared
OA liposomes using ethanol injection-sonication and
studied the pharmacokinetics of OA liposomes in rats
[17]. OA liposomes were almost spherical with a mean
diameter of (206.4 ± 4.7) nm. The encapsulation effi-
ciency of OA liposomes was over 90% without hemolyti-
cus. The pharmacokinetic parameters of liposomes were
better than those of non-liposomes [17].
Figure 1 Chemical structrue of oleanolic acid (OA).
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Proliposomes
The concept of proliposome was introduced to improve
the stability of liposome. Proliposomes are dry, free-
flowing particles that immediately form a liposomal sus-
pension when in contact with water [24]. Proliposome
technologies can produce liposome on a large scale and
replace the thin film method [25].
A new proliposome preparation method was used to
trap OA into the liposomes [26]. Particle size of the lipo-
somes was small and uniformly distributed. The entrap-
ment efficiency was (85.65 ± 7.96) % and increased when
pH was increased or the proportion of the the proportion
of the drug and the phosphatide (P/D) was increased
from 5:1 to 10:1. The liposomes increased the small
intestinal absorption of the drug as determined by the
isolated small intestinal absorption method, showing a
larger area under curve (AUC) in serosal fluid of prolipo-
some than that of the control group [27].
Self- microemulsifying drug delivery system
Composed of oils and surfactants, self-emulsifying drug
delivery systems (SEDDS) was reported to have many
advantages, especially in enhancing oral bioavailability of
poorly absorbed drugs [28]. Ideal isotropic including co-
solvents would disperse in the aqueous environment of
the gastrointestinal tract to form a fine oil-in-water emul-
sion under gentle agitation to improve the oral bioavail-
ability of the drug with poor water-solubility [29].
Compared to conventional emulsions, SNEDDS was
reported to be a thermodynamically and physically stable
formulation with high solubility and offer an improvement
in dissolution rates and extents of absorption, resulting in
more reproducible blood-time profiles [30].
Recently, OA SNEDDS was formulated with Sefsol 218,
Cremophor EL, Labrasol, and Transcutol P by pseudo-
ternary phase diagrams to identify self-emulsification
regions for the rational design. A remarkable increase in
dissolution was observed for the SNEDDS in comparison
with the commercial tablet. Oral absorption of OA from
SNEDDS showed a 2.4-fold increase in relative bioavail-
ability. An increased mean retention time of OA in rat
plasma was also observed [31]. These results suggest the
potentials of SNEDDS in improving dissolution and oral
bioavailability for poorly water-soluble triterpenoids.
Another study reported the preparation of OA self-
microemulsion with ethyl oleate/EL-40/alcohol self-
microemulsion system and quality evaluation of OA self-
microemulsion with the morphology, particle, diameter
distribution, physico-chemical properties and stability
[32]. The microemulsion was clear and transparent. The
microemulsion vesicles appeared as spherical liquid dro-
plets with a Transmission electron microscopy (TEM)
after diluted with average diameter of 49.8 nm. Properties
of the microemulsion were stable in the stability test. The
authors concluded that the self-microemulsion which
improved solubility was easy to prepare. In vitro dissolu-
tion and absorption kinetics of OA self-microemulsion
were studied with paddle method and in situ perfusion
method respectively. Dissolution of OA was significantly
increased by self-microemulsifying drug delivery system
compared with commercially available tablets [6]. OA
self-microemulsifying system significantly enhanced the
absorption of OA in the gastrointestinal tract and
improved its bioavailability [33].
Submicron emulsions
Submicron/nano emulsions are a system of at least two
nearly immiscible fluids dispersing one into another in the
form of droplets with diameter well below the micron level
[34]. Nano/submicron emulsions has drawn much attention
from the pharmaceutical, cosmetic and food industries [35].
Submicron/nano emulsions are expected to improve uptake
efficiency of lipophilic substances as particle absorption
rates in the gastrointestinal tract were correlated to the dro-
plet size [35]. This technology provides colloidal drug car-
riers for various therapeutic applications such as parenteral,
oral, ophthalmic or transdermal delivery systems [36]. Zhao
et al. developed and validated a simple yet robust HPLC
method for the quantitative determination of OA content
and partition coefficient of OA in a submicron emulsion-
based formulation [37].
Conclusion
Nanoparticulate drug delivery system enhances the dis-
solution rate and bioavailability of OA, providing a feasi-
ble formulation method for clinical applications.
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